Pancreatic cancer survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive pancreatic cancer for 10 or more years, 2013-2017, England and Wales

Age

Age that pancreatic cancer survival is highest, 2009-2013, England

 

Improvement

Pancreatic cancer survival in the UK has not changed in the last 40 years

 

24.8% of males survive pancreatic cancer for at least one year. This falls to 6.5% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with pancreatic cancer during 2013-2017 in England.[1] Survival for females at one year is 26.2% and falls to 8.1% surviving for at least five years. Survival for females is higher than for than for males at one year, and higher than for at five years.

Pancreatic Cancer Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 
Pancreatic cancer survival continues to fall beyond five years after diagnosis. 5.0% of people are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with pancreatic cancer during 2013-2017 in England.[1]

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for pancreatic cancer is highest in the youngest men and women and decreases with increasing age. Five-year net survival in men ranges from 17% in 15-49 year-olds to 2% in 80-99 year-olds for patients diagnosed with pancreatic cancer in England during 2009-2013.[1] In women, five-year survival ranges from 26% to 2% in the same age groups. Five-year survival is significantly higher in women compared with men in the 15-49 age group.

Pancreatic Cancer (C25), Five-Year Net Survival by Age, England, 2009-2013

Last reviewed:

One-year age-standardised Open a glossary item net survival for pancreatic cancer in men has increased from 10% during 1971-1972 to 22% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 11 percentage points.[1] In women, one-year survival has increased from 11% to 20% over the same time period (a difference of 9 percentage points).

Pancreatic Cancer (C25), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Unlike the majority of cancers, five- and ten-year survival for pancreatic cancer has not shown much improvement since the early 1970s. In men and women, five-year age-standardised net survival for pancreatic cancer has not increased significantly between 1971-1972 and 2010-2011 in England and Wales.[1]

Pancreatic Cancer (C25), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year survival has followed the same trend as five-year survival since the early 1970s, with no significant increase in either men or women between 1971-1972 and 2010-2011 in England and Wales.[1] Overall, only 1% of people diagnosed with pancreatic cancer today are predicted to survive their disease for at least ten years.

Pancreatic Cancer (C25), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request, 2014.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C25

Last reviewed:

Five-year relative survival for pancreatic cancer in men in England (4%) is below the average for Europe (6%). Wales (4%), Scotland (4%) and Northern Ireland (2%) are also below the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 2% (Northern Ireland) to 11% (Croatia).[1]

Five-year relative survival for pancreatic cancer in women in England (5%) is below the average for Europe (8%) but Wales (7%) is similar to the European average.[1] No five-year survival data is available for Scotland and Northern Ireland. Across the European countries for which data is available, five-year relative survival in women ranges from 4% (The Netherlands) to 12% (Belgium).[1]

Pancreatic Cancer (C25), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, pancreatic cancer (C25).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.